Switch theme
Sign up to access all valuation multiples
Toleranzia AB is a Swedish biotechnology company. It develops drugs that harness the power of the immune system to treat autoimmune orphan diseases. The company uses its tolerance technology for drug development, which is based on the identification of disease-specific proteins that are developed into biological drugs, specific to each autoimmune disease. Its drug development pipeline includes TOL2, which is being developed for the treatment of autoimmune orphan disease myasthenia gravis, and TOL3, being developed for another indication in autoimmune orphan diseases, ANCA vasculitis.
2011
10
Last FY Revenue n/a
Last FY EBITDA $0.4M
$11.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Toleranzia achieved revenue of n/a and an EBITDA of $0.4M.
Toleranzia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Toleranzia valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | $3.1M | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | $0.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | $0.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | $1.0M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Toleranzia's stock price is SEK 0 (or $0).
Toleranzia has current market cap of SEK 121M (or $12.5M), and EV of SEK 107M (or $11.1M).
See Toleranzia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.1M | $12.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Toleranzia has market cap of $12.5M and EV of $11.1M.
Toleranzia's trades at n/a EV/Revenue multiple, and 29.1x EV/EBITDA.
Equity research analysts estimate Toleranzia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Toleranzia's P/E ratio is not available.
See valuation multiples for Toleranzia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.5M | XXX | $12.5M | XXX | XXX | XXX |
| EV (current) | $11.1M | XXX | $11.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 29.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 28.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 12.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialToleranzia's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.3M for the same period.
Toleranzia's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Toleranzia's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Toleranzia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Toleranzia acquired XXX companies to date.
Last acquisition by Toleranzia was XXXXXXXX, XXXXX XXXXX XXXXXX . Toleranzia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Toleranzia founded? | Toleranzia was founded in 2011. |
| Where is Toleranzia headquartered? | Toleranzia is headquartered in Sweden. |
| How many employees does Toleranzia have? | As of today, Toleranzia has 10 employees. |
| Is Toleranzia publicy listed? | Yes, Toleranzia is a public company listed on STO. |
| What is the stock symbol of Toleranzia? | Toleranzia trades under TOL ticker. |
| When did Toleranzia go public? | Toleranzia went public in 2015. |
| Who are competitors of Toleranzia? | Similar companies to Toleranzia include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Toleranzia? | Toleranzia's current market cap is $12.5M |
| Is Toleranzia profitable? | Yes, Toleranzia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
